283 related articles for article (PubMed ID: 18185481)
21. Urinary Tract Cancer in Lynch Syndrome; Increased Risk in Carriers of MSH2 Mutations.
Joost P; Therkildsen C; Dominguez-Valentin M; Jönsson M; Nilbert M
Urology; 2015 Dec; 86(6):1212-7. PubMed ID: 26385421
[TBL] [Abstract][Full Text] [Related]
22. Metachronous colorectal cancer risk for mismatch repair gene mutation carriers: the advantage of more extensive colon surgery.
Parry S; Win AK; Parry B; Macrae FA; Gurrin LC; Church JM; Baron JA; Giles GG; Leggett BA; Winship I; Lipton L; Young GP; Young JP; Lodge CJ; Southey MC; Newcomb PA; Le Marchand L; Haile RW; Lindor NM; Gallinger S; Hopper JL; Jenkins MA
Gut; 2011 Jul; 60(7):950-7. PubMed ID: 21193451
[TBL] [Abstract][Full Text] [Related]
23. Epigenetic mechanisms in the pathogenesis of Lynch syndrome.
Peltomäki P
Clin Genet; 2014 May; 85(5):403-12. PubMed ID: 24443998
[TBL] [Abstract][Full Text] [Related]
24. A review of mismatch repair gene transcripts: issues for interpretation of mRNA splicing assays.
Thompson BA; Martins A; Spurdle AB
Clin Genet; 2015 Feb; 87(2):100-8. PubMed ID: 24989436
[TBL] [Abstract][Full Text] [Related]
25. Semiquantitative assessment of immunohistochemistry for mismatch repair proteins in Lynch syndrome.
Barrow E; Jagger E; Brierley J; Wallace A; Evans G; Hill J; McMahon R
Histopathology; 2010 Feb; 56(3):331-44. PubMed ID: 20459533
[TBL] [Abstract][Full Text] [Related]
26. Long-range PCR facilitates the identification of PMS2-specific mutations.
Clendenning M; Hampel H; LaJeunesse J; Lindblom A; Lockman J; Nilbert M; Senter L; Sotamaa K; de la Chapelle A
Hum Mutat; 2006 May; 27(5):490-5. PubMed ID: 16619239
[TBL] [Abstract][Full Text] [Related]
27. Integrated analysis of unclassified variants in mismatch repair genes.
Pastrello C; Pin E; Marroni F; Bedin C; Fornasarig M; Tibiletti MG; Oliani C; Ponz de Leon M; Urso ED; Della Puppa L; Agostini M; Viel A
Genet Med; 2011 Feb; 13(2):115-24. PubMed ID: 21239990
[TBL] [Abstract][Full Text] [Related]
28. Molecular characterization of the spectrum of genomic deletions in the mismatch repair genes MSH2, MLH1, MSH6, and PMS2 responsible for hereditary nonpolyposis colorectal cancer (HNPCC).
van der Klift H; Wijnen J; Wagner A; Verkuilen P; Tops C; Otway R; Kohonen-Corish M; Vasen H; Oliani C; Barana D; Moller P; Delozier-Blanchet C; Hutter P; Foulkes W; Lynch H; Burn J; Möslein G; Fodde R
Genes Chromosomes Cancer; 2005 Oct; 44(2):123-38. PubMed ID: 15942939
[TBL] [Abstract][Full Text] [Related]
29. [Combining clinical investigation with molecular genetics research: to push forward the study of hereditary colorectal carcinoma into a higher level in China].
Li S
Zhonghua Yi Xue Za Zhi; 2002 Oct; 82(20):1369-70. PubMed ID: 12613476
[No Abstract] [Full Text] [Related]
30. Implementation of tumor testing for lynch syndrome in endometrial cancers at a large academic medical center.
Moline J; Mahdi H; Yang B; Biscotti C; Roma AA; Heald B; Rose PG; Michener C; Eng C
Gynecol Oncol; 2013 Jul; 130(1):121-6. PubMed ID: 23612316
[TBL] [Abstract][Full Text] [Related]
31. Functional testing strategy for coding genetic variants of unclear significance in MLH1 in Lynch syndrome diagnosis.
Hinrichsen I; Schäfer D; Langer D; Köger N; Wittmann M; Aretz S; Steinke V; Holzapfel S; Trojan J; König R; Zeuzem S; Brieger A; Plotz G
Carcinogenesis; 2015 Feb; 36(2):202-11. PubMed ID: 25477341
[TBL] [Abstract][Full Text] [Related]
32. Constitutive deficiency in DNA mismatch repair: is it time for Lynch III?
Felton KE; Gilchrist DM; Andrew SE
Clin Genet; 2007 Jun; 71(6):499-500. PubMed ID: 17539898
[TBL] [Abstract][Full Text] [Related]
33. Interobserver variability in the evaluation of mismatch repair protein immunostaining.
Klarskov L; Ladelund S; Holck S; Roenlund K; Lindebjerg J; Elebro J; Halvarsson B; von Salomé J; Bernstein I; Nilbert M
Hum Pathol; 2010 Oct; 41(10):1387-96. PubMed ID: 20573374
[TBL] [Abstract][Full Text] [Related]
34. Pleomorphic rhabdomyosarcoma in a patient with hereditary nonpolyposis colorectal cancer.
Cranmer LD; Chen CC; Morgan S; Martino G; Ray J
J Clin Oncol; 2013 Mar; 31(7):e108-10. PubMed ID: 23319697
[No Abstract] [Full Text] [Related]
35. Constitutive deficiency in DNA mismatch repair.
Felton KE; Gilchrist DM; Andrew SE
Clin Genet; 2007 Jun; 71(6):483-98. PubMed ID: 17539897
[TBL] [Abstract][Full Text] [Related]
36. PMS2 involvement in patients suspected of Lynch syndrome.
Niessen RC; Kleibeuker JH; Westers H; Jager PO; Rozeveld D; Bos KK; Boersma-van Ek W; Hollema H; Sijmons RH; Hofstra RM
Genes Chromosomes Cancer; 2009 Apr; 48(4):322-9. PubMed ID: 19132747
[TBL] [Abstract][Full Text] [Related]
37. [Lynch syndrome-related endometrial carcinoma].
Pang SJ; Guo DH
Zhonghua Bing Li Xue Za Zhi; 2012 Jul; 41(7):494-7. PubMed ID: 22932468
[No Abstract] [Full Text] [Related]
38. Identification of cancer patients with Lynch syndrome: clinically significant discordances and problems in tissue-based mismatch repair testing.
Bartley AN; Luthra R; Saraiya DS; Urbauer DL; Broaddus RR
Cancer Prev Res (Phila); 2012 Feb; 5(2):320-7. PubMed ID: 22086678
[TBL] [Abstract][Full Text] [Related]
39. [Should we systematically screen for Lynch syndrome in patients with upper urinary tract carcinoma?].
Olagui GS; Pignot G; Rouquette A; Vieillefond A; Amsellem-Ouazana D; de Longchamps NB; Radenen B; Zerbib M; Terris B
Bull Cancer; 2014 Feb; 101(2):144-50. PubMed ID: 24556207
[TBL] [Abstract][Full Text] [Related]
40. Use of molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset colorectal cancer.
Southey MC; Jenkins MA; Mead L; Whitty J; Trivett M; Tesoriero AA; Smith LD; Jennings K; Grubb G; Royce SG; Walsh MD; Barker MA; Young JP; Jass JR; St John DJ; Macrae FA; Giles GG; Hopper JL
J Clin Oncol; 2005 Sep; 23(27):6524-32. PubMed ID: 16116158
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
